Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 9 years, Simcere Pharmaceutical Group's highest Yield on Cost was 3.47. The lowest was 1.23. And the median was 2.11.
SMHGF's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.335 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Simcere Pharmaceutical Group (OTCPK:SMHGF) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Simcere Pharmaceutical Group 5-Year Yield-on-Cost % Related Terms
SMHGF vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % falls into.
Simcere Pharmaceutical Group 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Simcere Pharmaceutical Group (SMHGF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Simcere Pharmaceutical Group and its competitors. Over the past decade, Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % has ranged from 1.23 to 3.47. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #308 out of 514 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % too high?
Simcere Pharmaceutical Group's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.23 to a high of 3.47. Based on the distribution chart, Simcere Pharmaceutical Group ranks #308 out of 514 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #308 out of 514 companies for 5-Year Yield-on-Cost %. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. Historically, Simcere Pharmaceutical Group's own 5-Year Yield-on-Cost % has ranged from 1.23 to 3.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (SMHGF) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is $1.26, compared to a current price of $1.49 — trading 18.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.49 is trading 18.2% above its estimated GF Value™ of $1.26.
Key valuation signals for SMHGF:
5-Year Yield-on-Cost %: 0.00
GF Value™: $1.26 vs. price of $1.49 (18.2% above fair value)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for SMHGF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
